Cite
MLA Citation
Edit Remák et al.. “Understanding relative survival outcomes for patients with cutaneous T-cell lymphoma (CTCL) subtypes mycosis fungoides and Sézary syndrome treated with mogamulizumab or vorinostat: combining Australian real-world evidence and MAVORIC phase 3 trial data.” European journal of cancer, vol. 156, n.d., pp. S18–. http://access.bl.uk/ark:/81055/vdc_100144488908.0x000022